Page last updated: 2024-12-08
be 4-4-4-4
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BE 4-4-4-4: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 368998 |
| CHEMBL ID | 551489 |
| SCHEMBL ID | 429223 |
| MeSH ID | M0220441 |
Synonyms (23)
| Synonym |
|---|
| NCI60_013495 |
| NCIMECH_000262 |
| NSC640506 , |
| PDSP2_000331 |
| PDSP1_000333 |
| 3,8,13,18-pentaazapentacosane pentahydrochloride |
| 1, 4-butanediamine, {n-[4-(ethylamino)butyl]-n'-[4-[[4-(ethylamino)butyl]amino]butyl]-,} pentahydrochloride |
| sl-11061 |
| n-ethyl-n'-[4-[4-[4-(ethylamino)butylamino]butylamino]butyl]butane-1,4-diamine |
| ethyl[4-({4-[(4-{[4-(ethylamino)butyl]amino}butyl)amino]butyl}amino)butyl]amine |
| n~1~-ethyl-n~4~-(4-((4-((4-(ethylamino)butyl)amino)butyl)amino)butyl)-1,4-butanediamine hydrochloride |
| 147510-59-6 |
| CHEMBL551489 |
| 3,8,13,18,23-pentaazapentacosane |
| 1,19-bis(ethylamino)-5,10,15-triazanonadecane |
| be4444 |
| cas_147510-59-6 |
| bdbm86161 |
| papc-hcl |
| be 4-4-4-4 |
| 1,4-butanediamine, n-(4-(ethylamino)butyl)-n'-(4-((4-(ethylamino)butyl)amino)butyl)- |
| SCHEMBL429223 |
| DTXSID50163735 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " dose of 20 mg/kg ranged between 30 and 33 microgram/ml, the terminal elimination half-life was 94 min, and the volume of distribution (Vdss) was 850 ml/kg." | ( Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice. Callery, PS; Eddington, ND; Egorin, MJ; Eiseman, JL; Sentz, DL; Yuan, ZM, 1996) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Urinary excretion of parent BE-4-4-4-4 in the first 24 h after dosing accounted for less than 30% of the delivered dose." | ( Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice. Callery, PS; Eddington, ND; Egorin, MJ; Eiseman, JL; Sentz, DL; Yuan, ZM, 1996) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID421192 | Antitumor activity against human LNCAP cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
| AID421191 | Antitumor activity against human DU145 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
| AID421193 | Antitumor activity against human PC3 cells | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Recent advances in the development of polyamine analogues as antitumor agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (83.33) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (94.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||